Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | PKM | P14618 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TDO2 | P48775 | 1/20 | 0.40 |
| ▸ | GRK2 | P25098 | 1/20 | 0.40 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL188080 | 0.85 | ALDH1A1 (0.50) | MAPTTDP1SMN1; SMN2PKMPOLB | |
| SCHEMBL30882179 | 0.85 | ALDH1A1 (0.50) | MAPTTDP1SMN1; SMN2PKMPOLB | |
| SCHEMBL3620365 | 0.84 | ALDH1A1 (0.49) | MAPTTDP1SMN1; SMN2POLBALDH1A1 | |
| SCHEMBL9744548 | 0.82 | CLCN2 (0.46) | MAPTTDP1PKMCES2CES1 | |
| Hydrochloric Acid SCHEMBL5191753 | 0.80 | MAPT (0.38) | MAPTTDP1SMN1; SMN2PKMALDH1A1 | |
| SCHEMBL16887793 | 0.79 | ALDH1A1 (0.61) | MAPTTDP1SMN1; SMN2POLBALDH1A1 | |
| SCHEMBL16168119 | 0.79 | KEAP1 (0.49) | MAPTCES2CES1ALDH1A1KMT2A | |
| SCHEMBL3620098 | 0.79 | CA1 (0.38) | MAPTTDP1ALDH1A1MEN1KMT2A | |
| SCHEMBL8118450 | 0.78 | MAP2K1 (0.45) | KMT2A | |
| Hydrochloric Acid SCHEMBL28780309 | 0.77 | CXCL8 (0.54) | MAPTSMN1; SMN2PKMALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4687443-A1 | METHOD FOR FUNCTIONALISING A SOLID SUBSTRATE WITH A PEPTIDE CONJUGATE | Genepep (FR) | 2026-02-11 | — | — | EP | disclosed |
| WO-2024208878-A1 | METHOD FOR FUNCTIONALISING A SOLID SUBSTRATE WITH A PEPTIDE CONJUGATE | GENEPEP (FR) | 2024-10-10 | — | — | WO | disclosed |
| US-20230414702-A1 | COMPOUNDS AND PHARMACEUTICAL USE THEREOF IN THE TREATMENT OF CANCER | PEPKON SAS (FR) | 2023-12-28 | — | — | US | disclosed |
| US-11759496-B2 | Compounds and pharmaceutical use thereof in the treatment of cancer | Karoyan, Philippe (FR) | 2023-09-19 | — | — | US | disclosed |
| WO-2023055702-A1 | MAIN PROTEASE (M PRO) INHIBITORS AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2023-04-06 | — | — | WO | disclosed |
| CN-115160311-A | Bifunctional compound for EGFR degradation and application thereof | 北京康辰药业股份有限公司 | 2022-10-11 | — | — | CN | disclosed |
| EP-3454879-B1 | NEW COMPOUNDS AND PHARMACEUTICAL USE THEREOF IN THE TREATMENT OF CANCER | INST NAT SANTE RECH MED (FR) | 2021-12-22 | — | — | EP | disclosed |
| US-10851119-B2 | Boron-containing diacylhydrazines | INTREXON CORPORATION (US) | 2020-12-01 | — | — | US | disclosed |
| US-20200157122-A1 | BORON-CONTAINING DIACYLHYDRAZINES | INTREXON CORP (US) | 2020-05-21 | — | — | US | disclosed |
| CN-107406373-B | Boron-containing diacylhydrazine compounds | 英特瑞克斯顿股份有限公司 | 2020-04-28 | — | — | CN | disclosed |
| EP-1307214-A1 | HIGHLY HOMOGENEOUS MOLECULAR MARKERS FOR ELECTROPHORESIS | INVITROGEN CORPORATION (US) | 2003-05-07 | — | — | EP | disclosed |
| EP-1076563-A4 | DIPEPTIDE CASPASE INHIBITORS AND THE USE THEREOF | CYTOVIA INC (US) | 2003-04-23 | — | — | EP | disclosed |
| US-20020155455-A1 | Highly homogeneous molecular markers for electrophoresis | INVITROGEN CORPORATION | 2002-10-24 | — | — | US | disclosed |
| EP-1220869-A1 | CASPASE INHIBITORS FOR THE TREATMENT AND PREVENTION OF CHEMOTHERAPY AND RADIATION THERAPY INDUCED CELL DEATH | Cytovia, Inc. (US) | 2002-07-10 | — | — | EP | disclosed |
| WO-2002013848-A1 | HIGHLY HOMOGENEOUS MOLECULAR MARKERS FOR ELECTROPHORESIS | INVITROGEN CORPORATION (US) | 2002-02-21 | — | — | WO | disclosed |
| CN-1297354-A | Dipeptide caspase inhibitors and use thereof | CYTOVIA INC (US) | 2001-05-30 | — | — | CN | disclosed |
| WO-2001027140-A1 | CASPASE INHIBITORS FOR THE TREATMENT AND PREVENTION OF CHEMOTHERAPY AND RADIATION THERAPY INDUCED CELL DEATH | CYTOVIA, INC. (US) | 2001-04-19 | — | — | WO | disclosed |
| EP-1076563-A1 | DIPEPTIDE CASPASE INHIBITORS AND THE USE THEREOF | Cytovia, Inc. (US) | 2001-02-21 | — | — | EP | disclosed |
| US-6153591-A | PROTECTING NERVOUS SYSTEM FOLLOWING FOCAL ISCHEMIA AND GLOBAL ISCHEMIA; ALZHEIMER'S DISEASE, HUNTINGTON'S DISEASE, PRION DISEASES, PARKINSON'S DISEASE, MULTIPLE SCLEROSIS, AMYOTROPHIC LATERAL SCLEROSIS, ALOPACIA, RHEUMATOID ARTHRITIS | CYTOVIA, INC. (US) | 2000-11-28 | — | — | US | disclosed |
| WO-1999047154-A1 | DIPEPTIDE CASPASE INHIBITORS AND THE USE THEREOF | CYTOVIA, INC. (US) | 1999-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10851119-B2 | Boron-containing diacylhydrazines | CD22, BRDT, BCR | MAPT 4167/4885TDP1 2173/4885SMN1; SMN2 1417/4885 |
| US-20200157122-A1 | BORON-CONTAINING DIACYLHYDRAZINES | CD22, BRDT, BCR | MAPT 4167/4885TDP1 2173/4885SMN1; SMN2 1417/4885 |
| US-11759496-B2 | Compounds and pharmaceutical use thereof in the treatment of cancer | VIP, RNASE1, ABCB11 | MAPT 4394/4885TDP1 1380/4885SMN1; SMN2 1842/4885 |
| US-20230414702-A1 | COMPOUNDS AND PHARMACEUTICAL USE THEREOF IN THE TREATMENT OF CANCER | VIP, RNASE1, ABCB11 | MAPT 4394/4885TDP1 1380/4885SMN1; SMN2 1842/4885 |
| US-20020155455-A1 | Highly homogeneous molecular markers for electrophoresis | CD44, HLA-C, HLA-A | MAPT 3603/4885TDP1 1068/4885SMN1; SMN2 4632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.